Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GISMM2001: Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients: a Prospective, Multi-center Phase III Study

NCT00950768 is registered in ClinicalTrials.gov with Azienda Ospedaliera San Giovanni Battista as lead sponsor.

NCT NCT00950768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00950768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GISMM2001: Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients: a Prospective, Multi-center Phase III Study
Lead sponsor
Azienda Ospedaliera San Giovanni Battista
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2002
Completion date
June 30, 2009
Enrollment
298 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diagnosis, multiple myeloma